Eli Lilly (LLY) Accounts Payables (2009 - 2026)

Eli Lilly (LLY) has reported Accounts Payables for 18 consecutive years, with $5.0 billion the latest figure, recorded in Q1 2026.

• Accounts Payables for Q1 2026 came in at $5.0 billion, up 46.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.0 billion (up 46.11% YoY), and the FY2025 annual result was $5.4 billion, up 66.58% from the prior year.
• Accounts Payables was $5.0 billion for Q1 2026 at Eli Lilly, down from $5.4 billion in the prior quarter.
• Over five years, Accounts Payables peaked at $5.4 billion in Q4 2025 and troughed at $1.4 billion in Q1 2022.
• Average Accounts Payables over 5 years is $2.9 billion, with a median of $2.6 billion recorded in 2023.
• Year-over-year, Accounts Payables decreased 12.58% in 2022 and soared 66.58% in 2025.
• Over 5 years, Accounts Payables stood at $1.9 billion in 2022, then jumped by 34.61% to $2.6 billion in 2023, then grew by 24.25% to $3.2 billion in 2024, then surged by 66.58% to $5.4 billion in 2025, then retreated by 6.51% to $5.0 billion in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $5.0 billion in Q1 2026, $5.4 billion in Q4 2025, and $4.3 billion in Q3 2025.